Artificial Intelligence-Enabled Quantitative Plaque and Hemodynamic Analysis for Predicting Acute Coronary Syndrome Risk and Prevention Strategy: The EMERALD II Study

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Grant Support/Research Contract - Abbott; Philips; Boston Scientific Corporation; HeartFlow